Skip to main content
. Author manuscript; available in PMC: 2013 Sep 9.
Published in final edited form as: J Am Board Fam Med. 2009 Mar-Apr;22(2):187–195. doi: 10.3122/jabfm.2009.02.080059

Appendix Table 1.

Included Drug Groups Used by Patients

Drug Group and Included Classes*
Oral hypoglycemics
 Biguanides
 Sulfonylureas
 Nonsulfonylurea insulin secretagogues (Nateglinide, Repaglinide)
α-Glucosidase inhibitors
 Thiazolidinediones
 DPP-4 inhibitors
Long-acting insulin
 NPH
 NPH–regular mix
 Aspart protamine/Aspart mix
 Lispro protamine/Lispro mix
 Detemir (Levemir)
 Glargine (Lantus)
HMG-CoA reductase inhibitors (statins)
 All statins
ACE inhibitors/ARBs
 All ACE inhibitors and ARBs

ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker; DPP-4 = dipeptidyl peptidase-4; HMG-CoA = 3-hydroxy-3-methyl coenzyme A; NPH = neutral protamine Hagedorn.

*

Includes combination products for each drug group (e.g., glyburide–metformin).

Used for basal insulin coverage, either once or twice daily.

Insulin analogues.